---
title: 礼来公司获得美国批准用于早期阿尔茨海默病治疗
date: 2024-07-02T19:24:22.229Z
description: New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
tags: 
- companies
author: ft
---

[原文链接](https://ft.com/content/05fa6b43-ad9f-4b9b-a198-9a38d835ee31)

礼来公司获得美国批准用于早期阿尔茨海默病治疗

**礼来公司的阿尔茨海默病药物基逊拉获得美国批准**

- 礼来公司已获得美国批准，可以推出其早期阶段的阿尔茨海默病药物基逊拉（donanemab），其售价比竞争对手 Leqembi 高出 20%。
-该公司声称他们的治疗方法更有效，因为与生物制药和 Eisai 开发的竞争对手药物相比，他们的药物需要较少的治疗次数。
- 基逊拉靶向阿尔茨海默病患者脑中的淀粉样蛋白斑块，比 Leqembi 需要更少的输注频率，从而有可能降低医疗系统的成本。
- 预计该药物将以每年 32,000 美元的价格进入美国市场，并将可供美国超过 100 万早期阶段阿尔茨海默病患者使用。
- 尽管存在关于罕见副作用的担忧以及即将推出的 Leqembi 皮下注射版本带来的竞争，但礼来公司对基逊拉的成功仍持乐观态度。

---

 **Eli Lilly's Alzheimer's Drug Kisunla Receives US Approval**

- Eli Lilly has received approval from the United States to launch its early-stage Alzheimer’s drug, Kisunla (donanemab), which will be sold at a 20% higher price than its competitor Leqembi.
- The company claims that their treatment is more efficient as it requires fewer treatments compared to the rival medicine developed by Biogen and Eisai.
- Kisunla targets amyloid plaque, a protein buildup in Alzheimer's patients' brains, with less frequent infusions than Leqembi, potentially reducing costs for health systems.
- The drug is projected to enter the US market at a list price of $32,000 per year of treatment and will be available for more than 1 million early-stage patients suffering from Alzheimer's in the United States.
- Despite concerns about rare side effects and competition with an upcoming subcutaneous version of Leqembi, Eli Lilly remains optimistic about Kisunla's success.

[Source Link](https://ft.com/content/05fa6b43-ad9f-4b9b-a198-9a38d835ee31)

